Santa Cruz Police Receives Funding to Combat Illegal Tobacco Sales

Regulations by 2FIRSTS.ai
Feb.28.2024
Santa Cruz Police Receives Funding to Combat Illegal Tobacco Sales
Santa Cruz Police Department receives over $250,000 to combat illegal tobacco and e-cigarette sales to minors in California.

According to a report from KSBW on February 27, the Santa Cruz Police Department in California recently received over $250,000 in financial funding. This grant will be used to combat illegal sales of tobacco and e-cigarettes to minors.

 

As of now, authorities have received a total of $256,568 in funding from the state's Department of Justice tobacco settlement program. This funding will be used for several purposes:

 

  • Enforcing statewide retail flavor bans and similar local retail flavor ordinances.
  • Sue and penalize retailers who sell or promote tobacco products to individuals under the age of 21, including through online sales and marketing.
  • Provide education and information to tobacco retailers about state and local tobacco laws.
  • As well as investigating and inspecting the compliance of retail licenses.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
A patent published on February 24, 2026, by China Tobacco Hubei Industrial Co., Ltd. introduces a “nicotine jelly” product designed to combine rapid and sustained nicotine delivery. By integrating both free and microencapsulated nicotine, the product aims to address key limitations of traditional nicotine replacement therapy (NRT), while also raising new regulatory and product classification questions.
Innovation
Mar.18
JT Delivers Record FY2025 Results as RRP Accelerates and Ploom Expands Globally
JT Delivers Record FY2025 Results as RRP Accelerates and Ploom Expands Globally
JT reported record FY2025 revenue and adjusted operating profit, supported by combustible resilience and accelerating reduced-risk product growth. Heated tobacco volumes surged, led by Ploom. The group confirmed a major three-year RRP investment plan and projected further growth in 2026.
Feb.12
Imperial Brands Expands Blu Fruit-Flavour Offerings Following Consumer Preference Data
Imperial Brands Expands Blu Fruit-Flavour Offerings Following Consumer Preference Data
Imperial Brands has announced the launch of a new Sour Berry flavour for its Blu vape range. The product will launch across retail this month, with both the Blu bar kit and Blu pod pack carrying a recommended retail price of GBP 5.99 (approximately USD 7.79, based on 1 GBP ≈ 1.30 USD).
Apr.03 by 2FIRSTS.ai
Singapore New bill would raise maximum fines to S$200,000 for sellers and S$300,000 for smugglers
Singapore New bill would raise maximum fines to S$200,000 for sellers and S$300,000 for smugglers
A bill introduced in Singapore’s Parliament on Feb. 12 proposes major increases in penalties for vaping-related offences, including higher maximum fines for users, sellers and smugglers. The draft would also rename the current Tobacco (Control of Advertisements and Sale) Act as the Tobacco and Vaporisers Control Act.
Feb.28 by 2FIRSTS.ai
New York Says Seized Illegal Vape Shipment Had Retail Value of USD 2.2 Million to USD 3.5 Million
New York Says Seized Illegal Vape Shipment Had Retail Value of USD 2.2 Million to USD 3.5 Million
New York state health officials said a joint operation last week involving the State Department of Health, Nassau County police and local health officials intercepted about 14 tons of illegal vape products that were intended for local distributors and smoke shops.
Mar.20 by 2FIRSTS.ai
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
During the “Toxicological Profile” session at FDA’s Feb 10 PMTA roundtable, officials outlined the carcinogenicity tiering system and Excess Lifetime Cancer Risk (ELCR) framework used in ENDS reviews under the APPH standard. Small manufacturers questioned database transparency, exposure assumptions, and the existence of clear compliance benchmarks. FDA reiterated toxicological risk is assessed case by case within a broader population-level determination.
Feb.11